jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

CD34

Immunity
image

Report in 72Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Flow cytometry panel of immune cell surface markers.

₹2,738₹3,911

30% OFF

CD34 Test - Comprehensive Medical Information Guide

  • Why is it done?
    • CD34 is a marker protein found on hematopoietic stem cells and progenitor cells. This test measures the number and percentage of CD34-positive cells in blood or bone marrow samples.
    • Assess stem cell mobilization before peripheral blood stem cell collection for transplantation or leukapheresis procedures.
    • Evaluate effectiveness of mobilization strategies and determine optimal timing for cell collection.
    • Diagnose and monitor hematologic malignancies, particularly acute myeloid leukemia (AML) and other leukemias.
    • Assess bone marrow recovery and engraftment after stem cell or bone marrow transplantation.
    • Evaluate patients with primary immunodeficiencies or severe combined immunodeficiency (SCID).
    • Monitor HIV infection and assess immune reconstitution in patients on antiretroviral therapy.
    • Performed routinely during stem cell mobilization procedures using cytokine therapy (G-CSF or other growth factors).
  • Normal Range
    • Normal CD34+ cell count in peripheral blood: Less than 100 cells/μL (or <0.1% of total white blood cells) in healthy individuals.
    • Optimal CD34+ cell count for apheresis collection: Greater than 10 cells/μL (or ≥0.05% of total cells) indicates adequate mobilization for successful collection.
    • CD34+ cell count in bone marrow: 0.5-5% of nucleated bone marrow cells.
    • Units of measurement: Cells/μL, percentage (%), or cells/mm³.
    • Low CD34+ counts (<10 cells/μL): May indicate inadequate stem cell mobilization, poor response to growth factors, or bone marrow disorders.
    • Elevated CD34+ counts (>1000 cells/μL): May indicate excellent mobilization response or possible leukemic involvement depending on clinical context.
  • Interpretation
    • CD34+ counts 10-50 cells/μL: Adequate mobilization achieved; patient is ready for apheresis collection with good prognosis for obtaining sufficient stem cells for transplantation.
    • CD34+ counts 50-100 cells/μL: Excellent mobilization response; expected to obtain large numbers of stem cells during collection.
    • CD34+ counts <10 cells/μL: Poor mobilization; collection not recommended; may need alternative mobilization strategy, increased growth factor doses, or alternative therapy.
    • Elevated CD34+ in bone marrow aspirate/biopsy (>5%): Suggestive of acute leukemia or myelodysplastic syndrome; requires further evaluation and risk stratification.
    • Post-transplant CD34+ recovery: Progressive increase in CD34+ counts indicates successful engraftment and bone marrow recovery after transplantation.
    • Persistently low CD34+ counts after transplant: May indicate graft failure, slow engraftment, or inadequate stem cell dose at transplant.
    • Factors affecting CD34+ counts: Age, prior chemotherapy, radiation exposure, smoking status, disease type, time of day (circadian variation), corticosteroid use, recent infections, and G-CSF sensitivity.
    • Disease-specific patterns: Lymphoma and myeloma patients typically mobilize well; patients with heavily pretreated disease or bone marrow involvement may have poor mobilization.
  • Associated Organs
    • Primary organ system: Hematopoietic (blood-forming) system; bone marrow, peripheral blood, and lymphoid organs.
    • Bone marrow: Primary source of hematopoietic stem cells; abnormal CD34 levels indicate marrow disorders or malignancies.
    • Conditions associated with elevated CD34+ cells: Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), blast crisis, and leukostasis.
    • Conditions associated with poor mobilization (low CD34+ counts): Aplastic anemia, myelodysplasia, severe chemotherapy-induced marrow damage, marrow fibrosis, autologous stem cell transplant failure, and immunodeficiency disorders.
    • Potential complications from abnormal results: Leukemia progression, graft failure after transplantation, inability to obtain sufficient stem cells, leukostasis with cerebral/pulmonary complications, organ damage from leukemic infiltration, infections due to immune deficiency.
    • Immune system involvement: CD34+ cells are critical for immune reconstitution; important marker in evaluating immunodeficiency, HIV progression, and post-transplant immune recovery.
  • Follow-up Tests
    • Additional CD34+ monitoring: Repeat CD34 counts daily or every other day if counts are <10 cells/μL to assess mobilization response or post-transplant recovery.
    • Flow cytometry panel: Multi-parameter flow cytometry with additional markers (CD19, CD33, CD45, CD13, CD14) to characterize cell populations and detect leukemia or other blood disorders.
    • Complete blood count (CBC): Provides white blood cell, red blood cell, and platelet counts; essential for assessing overall hematologic status.
    • Bone marrow biopsy and aspirate: Indicated if elevated CD34 in peripheral blood or abnormal peripheral blood findings; allows morphologic evaluation and additional testing.
    • Cytochemistry and immunocytochemistry: Special stains and immunologic markers to classify acute leukemias and determine lineage.
    • Cytogenetics and molecular testing: Chromosomal analysis, FISH, and molecular mutations (FLT3, NPM1, TP53) for risk stratification in leukemia.
    • CD34+ subset analysis: Assessment of CD34+/CD38- cells (long-term repopulating cells) during mobilization or post-transplant monitoring.
    • Peripheral blood smear: Morphologic evaluation of blood cells to identify abnormal forms, blasts, or dysplasia.
    • Monitoring frequency for stem cell transplant patients: CD34+ counts checked weekly to monthly post-transplant until stable engraftment confirmed; then at longer intervals if clinically indicated.
    • CD4 and CD8 counts: Important in HIV patients or those with immune deficiencies to assess immune reconstitution alongside CD34 recovery.
  • Fasting Required?
    • Fasting requirement: No, fasting is not required for CD34 testing.
    • Dietary restrictions: None; patients may eat and drink normally before the test.
    • Medication considerations: Continue all regular medications unless specifically instructed otherwise; G-CSF should be continued as prescribed; no specific medications need to be avoided before testing.
    • Timing of G-CSF dose: CD34+ counts show circadian variation; for standardization, blood samples should be drawn at the same time daily, preferably in the morning.
    • Sample collection: Peripheral blood collected in EDTA (lavender-top) anticoagulant tube or specific tube per laboratory protocol; bone marrow aspirate in EDTA tube.
    • Patient preparation: No special preparation needed; comfortable clothing with accessible veins recommended; inform healthcare provider of any medications or supplements.
    • Post-collection instructions: Normal activities may be resumed immediately; apply pressure to venipuncture site if bleeding occurs; stay well hydrated.

How our test process works!

customers
customers